New research indicates that people who stop using new slimming jabs like Wegovy and Mounjaro can put back on shed pounds at a significantly accelerated pace than those who end traditional diet and exercise programs.
Findings released in a leading health publication demonstrates that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such medications should be informed of the risk of rapid rebound weight gain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of regain suggests a reversion to pre-treatment mass within about a year and a half.
Analyzing Treatments
The analysis, which looked at dozens of trials involving thousands of patients, compared the effects of these new drugs with conventional dieting.
The team point out that people who lose weight through lifestyle changes alone typically see a slower creep back—around 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Doctors suggest the mode of action of the injections explains the amplified weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 levels several times higher than normal could lead to the system to produce less of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making binge eating far more likely."
An Ongoing Disease?
Medical guidelines recommend the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians argue that, due to the likelihood of weight regain, the treatment might need to be long-term.
This opinion is supported by drug manufacturers, who note that the results "underscore the chronic nature of obesity," comparing it to managing diseases like hypertension.
Patient Testimonies
Individuals who have stopped the jabs explain a intense resurgence of cravings.
"I experienced a trigger that goes on and you're instantly ravenous," recalled one woman.
This challenge is exacerbated if patients have not developed sustainable lifestyle or habit changes during treatment.
Widespread Use
Survey data indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is greater among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and lasting health benefits likely depends on integrated lifestyle management.
